Health brief
Priority Review for Teva, Alpha Radiation at Hadassah, and West Nile Outbreak
FDA fast-tracks Teva's novel Tourette treatment, Hadassah performs a breakthrough brain cancer procedure, and health officials confront rising West Nile cases.
Health
The Health Ministry is escalating mosquito control across central Israel after West Nile infections jumped to 17 cases — signaling a widening seasonal outbreak.
BackgroundWest Nile virus is a mosquito-borne pathogen that can trigger severe neurological illness, encephalitis, or meningitis in vulnerable individuals. Health authorities conduct routine seasonal trapping and testing to monitor viral spread across urban municipalities during peak summer months.
- Hospitalized patients primarily presented with high fever, acute rash, and severe neurological complications including disorientation and confusion.
- Environmental protection agencies instructed local municipalities to accelerate chemical spraying and eliminate standing water reservoirs near residential neighborhoods.
- Municipal vector control teams face heightened scrutiny as warmer seasonal temperatures accelerate mosquito breeding cycles across central and southern districts.
Health
Hadassah's alpha radiation procedure destroyed recurrent glioblastoma tumors while protecting healthy tissue — opening a minimally invasive surgical path for terminal brain cancer.
BackgroundGlioblastoma remains an aggressive brain cancer with high recurrence rates following surgery and standard chemotherapy. The Alpha DaRT technology was co-developed by Hadassah neurosurgeons and Israeli firm Alpha Tau Medical to deliver targeted radiation directly into brain tumors.
- Alpha particles deliver high-energy radiation across a millimeter-range radius, destroying cancer cell DNA while leaving surrounding brain structures undamaged.
- The minimally invasive technique inserts seeds via surgical navigation tools, eliminating the need for open craniotomy in patients with late-stage recurring tumors.
- Clinical trial data showed local tumor control across all treated patients, offering a viable alternative for aggressive brain cancers resistant to chemotherapy.
Health
Teva secured FDA Priority Review for ecopipam — putting the Israeli drugmaker months away from launching the first novel Tourette treatment in 50 years.
BackgroundPetah Tikva-based Teva is expanding its innovative neuroscience portfolio alongside its core generic drug business to drive long-term growth. Ecopipam selectively blocks dopamine D1 receptors to control motor and vocal tics without causing the heavy sedation typical of traditional treatments.
- Phase 3 clinical trial data demonstrated a 53% reduction in tic relapse risk among pediatric patients treated over 12 weeks, validating the drug's novel dopamine-blocking mechanism.
- Priority Review status accelerates the FDA's evaluation timeline from ten months down to six months, positioning Teva for potential commercial launch in early 2027.
- The Orphan Drug designation grants seven years of market exclusivity upon approval, protecting Teva's investment in the niche pediatric movement disorder segment.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
